Health Care Utilization and Costs Associated With Blue-Light vs White-Light Cystoscopy: A Real-World Bladder Cancer Population.

Mark D Tyson^1,2, Mouneeb M Choudry^1,2, Chad McKee³, Shiv Kalaria³, Cerise James³, Nicole M Engel-Nitz⁴, Mary G Johnson⁴, Timothy L Barnes⁴

¹Department of Urology, Mayo Clinic, Phoenix, Arizona.

²Resident in the Department of Urology, Mayo Clinic School of Graduate Medical Education, Mayo Clinic College of Medicine and Science, Phoenix, Arizona.

³Medical Affairs, Photocure Inc, Princeton, New Jersey.

⁴Optum Life Sciences, Eden Prairie, Minnesota.

PubMed PMC DOI PDF

Abstract

PURPOSE: Compared with white-light cystoscopy (WLC), blue-light cystoscopy (BLC) enhances detection of non-muscle-invasive bladder cancer (NMIBC), especially carcinoma in situ (CIS). However, its effects on health care resource utilization and cost burden have not been fully elucidated. This study assessed the economic implications of BLC vs WLC. MATERIALS AND METHODS: We conducted a retrospectiv…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.